Last reviewed · How we verify
ropinirole PR/XR
Ropinirole PR/XR is a dopamine agonist that mimics the action of dopamine in the brain, helping to regulate movement and reduce symptoms of Parkinson's disease.
Ropinirole PR/XR is a dopamine agonist that mimics the action of dopamine in the brain, helping to regulate movement and reduce symptoms of Parkinson's disease. Used for Parkinson's disease, Restless legs syndrome.
At a glance
| Generic name | ropinirole PR/XR |
|---|---|
| Also known as | ropinirole IR-PR group |
| Sponsor | GlaxoSmithKline |
| Drug class | dopamine agonist |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Ropinirole works by binding to dopamine receptors in the brain, which helps to increase the amount of dopamine available for use. This can help to improve motor function and reduce symptoms of Parkinson's disease. Ropinirole is available in both immediate-release (PR) and extended-release (XR) formulations.
Approved indications
- Parkinson's disease
- Restless legs syndrome
Common side effects
- Nausea
- Dizziness
- Headache
- Fatigue
- Dyskinesia
Key clinical trials
- Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD) (PHASE2)
- Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |